Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196091 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,164
- Enrollment target
NCT01196091: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01196091 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,164 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01196091, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,164 participants
- Enrollment target
Study Summary
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in participants with active SLE.
Primary Outcome
Percentage of participants with a ≥ 5 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline. SELENA SLEDAI is calculated from 24 individual descriptors across 9 organ systems; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (0=none, 1=mild
Interventions
- DRUG Standard of Care
- DRUG LY2127399
- DRUG Placebo every 2 weeks
- DRUG Placebo every 4 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,164 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT01196091 record still lists
NCT01196091 is an interventional study that assigns participants to a tested intervention. Its 1,164 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (51% higher).
The record links to 0 conditions, and to 4 interventions - of which Standard of Care is the first listed.
NCT01196091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01196091 about?
NCT01196091 is a clinical study titled "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus". The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in participants with active SLE.
What is the current status of trial NCT01196091?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,164 participants. The study started on 2010-12. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01196091?
The interventions under investigation include: Standard of Care (DRUG), LY2127399 (DRUG), Placebo every 2 weeks (DRUG), Placebo every 4 weeks (DRUG).
Who is sponsoring clinical trial NCT01196091?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01196091's enrollment target sits among peer trials
1,164 238th of 2000 higher than 1,763 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia